ID   AGRB2_HUMAN             Reviewed;        1585 AA.
AC   O60241; B9EGK9; Q5T6K0; Q8NGW8; Q96GZ9;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   05-MAY-2009, sequence version 2.
DT   28-JUN-2023, entry version 201.
DE   RecName: Full=Adhesion G protein-coupled receptor B2 {ECO:0000303|PubMed:25713288};
DE   AltName: Full=Brain-specific angiogenesis inhibitor 2;
DE   Flags: Precursor;
GN   Name=ADGRB2 {ECO:0000312|HGNC:HGNC:944}; Synonyms=BAI2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Fetal brain;
RX   PubMed=9533023; DOI=10.1159/000134693;
RA   Shiratsuchi T., Nishimori H., Ichise H., Nakamura Y., Tokino T.;
RT   "Cloning and characterization of BAI2 and BAI3, novel genes homologous to
RT   brain-specific angiogenesis inhibitor 1 (BAI1).";
RL   Cytogenet. Cell Genet. 79:103-108(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Suwa M., Sato T., Okouchi I., Arita M., Futami K., Matsumoto S.,
RA   Tsutsumi S., Aburatani H., Asai K., Akiyama Y.;
RT   "Genome-wide discovery and analysis of human seven transmembrane helix
RT   receptor genes.";
RL   Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4), AND NUCLEOTIDE SEQUENCE
RP   [LARGE SCALE MRNA] OF 1293-1585 (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   CLEAVAGE BY FURIN, PROTEOLYTIC PROCESSING, MUTAGENESIS OF TRP-889; CYS-908
RP   AND SER-912, SUBUNIT, PROTEIN SEQUENCE OF 296-306, GLYCOSYLATION, FUNCTION,
RP   AND ACTIVITY REGULATION.
RX   PubMed=20367554; DOI=10.3109/10799891003671139;
RA   Okajima D., Kudo G., Yokota H.;
RT   "Brain-specific angiogenesis inhibitor 2 (BAI2) may be activated by
RT   proteolytic processing.";
RL   J. Recept. Signal Transduct. 30:143-153(2010).
RN   [6]
RP   INTERACTION WITH TAX1BP3.
RX   PubMed=21787750; DOI=10.1016/j.bbrc.2011.07.029;
RA   Zencir S., Ovee M., Dobson M.J., Banerjee M., Topcu Z., Mohanty S.;
RT   "Identification of brain-specific angiogenesis inhibitor 2 as an
RT   interaction partner of glutaminase interacting protein.";
RL   Biochem. Biophys. Res. Commun. 411:792-797(2011).
RN   [7]
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND GLYCOSYLATION AT SER-266.
RX   PubMed=25326458; DOI=10.1074/mcp.m114.043703;
RA   Noborn F., Gomez Toledo A., Sihlbom C., Lengqvist J., Fries E., Kjellen L.,
RA   Nilsson J., Larson G.;
RT   "Identification of chondroitin sulfate linkage region glycopeptides reveals
RT   prohormones as a novel class of proteoglycans.";
RL   Mol. Cell. Proteomics 14:41-49(2015).
RN   [8]
RP   NOMENCLATURE.
RX   PubMed=25713288; DOI=10.1124/pr.114.009647;
RA   Hamann J., Aust G., Arac D., Engel F.B., Formstone C., Fredriksson R.,
RA   Hall R.A., Harty B.L., Kirchhoff C., Knapp B., Krishnan A., Liebscher I.,
RA   Lin H.H., Martinelli D.C., Monk K.R., Peeters M.C., Piao X., Promel S.,
RA   Schoneberg T., Schwartz T.W., Singer K., Stacey M., Ushkaryov Y.A.,
RA   Vallon M., Wolfrum U., Wright M.W., Xu L., Langenhan T., Schioth H.B.;
RT   "International union of basic and clinical pharmacology. XCIV. Adhesion G
RT   protein-coupled receptors.";
RL   Pharmacol. Rev. 67:338-367(2015).
RN   [9]
RP   SUBCELLULAR LOCATION, VARIANT TRP-1465, CHARACTERIZATION OF VARIANT
RP   TRP-1465, INTERACTION WITH SH3GL2 AND GNAZ, AND FUNCTION.
RX   PubMed=28891236; DOI=10.1002/humu.23336;
RA   Purcell R.H., Toro C., Gahl W.A., Hall R.A.;
RT   "A disease-associated mutation in the adhesion GPCR BAI2 (ADGRB2) increases
RT   receptor signaling activity.";
RL   Hum. Mutat. 38:1751-1760(2017).
CC   -!- FUNCTION: Orphan G-protein coupled receptor involved in cell adhesion
CC       and probably in cell-cell interactions. Activates NFAT-signaling
CC       pathway, a transcription factor, via the G-protein GNAZ
CC       (PubMed:20367554, PubMed:28891236). Involved in angiogenesis inhibition
CC       (By similarity). {ECO:0000250|UniProtKB:Q8CGM1,
CC       ECO:0000269|PubMed:20367554, ECO:0000269|PubMed:28891236}.
CC   -!- ACTIVITY REGULATION: Receptor activity is regulated by proteolytic
CC       processing. The long N-terminal has a an inhibitory effect on the
CC       constitutive signaling activity. Removal of the N-terminal region
CC       induces an increase of the receptor activity.
CC       {ECO:0000269|PubMed:20367554, ECO:0000269|PubMed:28891236}.
CC   -!- SUBUNIT: Heterodimer of 2 chains generated by proteolytic processing;
CC       the large extracellular N-terminal fragment and the membrane-bound C-
CC       terminal fragment predominantly remain associated and non-covalently
CC       linked. Interacts with GABPB2 (By similarity). Interacts (via carboxy-
CC       terminus) with TAX1BP3 (PubMed:21787750). Interacts with GNAZ
CC       (PubMed:28891236). Interacts with SH3GL2 (PubMed:28891236).
CC       {ECO:0000250|UniProtKB:Q8CGM1, ECO:0000269|PubMed:21787750,
CC       ECO:0000269|PubMed:28891236}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:28891236};
CC       Multi-pass membrane protein {ECO:0000255}. Secreted
CC       {ECO:0000269|PubMed:25326458}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=O60241-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O60241-2; Sequence=VSP_037047;
CC       Name=3;
CC         IsoId=O60241-3; Sequence=VSP_037045;
CC       Name=4;
CC         IsoId=O60241-4; Sequence=VSP_037046, VSP_037047;
CC   -!- TISSUE SPECIFICITY: Detected in cerebrospinal fluid (at protein level)
CC       (PubMed:25326458). Strongly expressed in brain. Also detected in heart,
CC       thymus, skeletal muscle, and different cell lines.
CC       {ECO:0000269|PubMed:25326458}.
CC   -!- PTM: Autoproteolytically processed at the GPS domain; this cleavage
CC       modulates receptor activity. Additionally, furin is involved in the
CC       cleavage at another site, in the middle of the extracellular domain,
CC       generating a soluble fragment. {ECO:0000269|PubMed:20367554}.
CC   -!- PTM: Glycosylated. {ECO:0000269|PubMed:20367554}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 2 family.
CC       Adhesion G-protein coupled receptor (ADGR) subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA25362.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB005298; BAA25362.1; ALT_INIT; mRNA.
DR   EMBL; AB065648; BAC05874.1; -; Genomic_DNA.
DR   EMBL; AC114488; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL354919; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC009035; AAH09035.1; -; mRNA.
DR   EMBL; BC136533; AAI36534.1; -; mRNA.
DR   CCDS; CCDS346.2; -. [O60241-1]
DR   CCDS; CCDS72746.1; -. [O60241-4]
DR   CCDS; CCDS72747.1; -. [O60241-2]
DR   PIR; T00027; T00027.
DR   RefSeq; NP_001281264.1; NM_001294335.1. [O60241-2]
DR   RefSeq; NP_001281265.1; NM_001294336.1. [O60241-4]
DR   RefSeq; XP_011540150.1; XM_011541848.2.
DR   RefSeq; XP_011540151.1; XM_011541849.2.
DR   RefSeq; XP_016857388.1; XM_017001899.1. [O60241-1]
DR   RefSeq; XP_016857389.1; XM_017001900.1. [O60241-2]
DR   RefSeq; XP_016857394.1; XM_017001905.1. [O60241-4]
DR   AlphaFoldDB; O60241; -.
DR   SMR; O60241; -.
DR   BioGRID; 107052; 9.
DR   IntAct; O60241; 9.
DR   MINT; O60241; -.
DR   STRING; 9606.ENSP00000362759; -.
DR   MEROPS; P02.029; -.
DR   TCDB; 9.A.14.6.6; the g-protein-coupled receptor (gpcr) family.
DR   CarbonylDB; O60241; -.
DR   GlyCosmos; O60241; 8 sites, No reported glycans.
DR   GlyGen; O60241; 8 sites.
DR   iPTMnet; O60241; -.
DR   PhosphoSitePlus; O60241; -.
DR   BioMuta; ADGRB2; -.
DR   jPOST; O60241; -.
DR   MassIVE; O60241; -.
DR   PaxDb; O60241; -.
DR   PeptideAtlas; O60241; -.
DR   ProteomicsDB; 49271; -. [O60241-1]
DR   ProteomicsDB; 49272; -. [O60241-2]
DR   ProteomicsDB; 49273; -. [O60241-3]
DR   ProteomicsDB; 49274; -. [O60241-4]
DR   Antibodypedia; 16794; 324 antibodies from 33 providers.
DR   DNASU; 576; -.
DR   Ensembl; ENST00000373655.6; ENSP00000362759.2; ENSG00000121753.13. [O60241-2]
DR   Ensembl; ENST00000373658.8; ENSP00000362762.3; ENSG00000121753.13. [O60241-1]
DR   Ensembl; ENST00000527361.5; ENSP00000435397.1; ENSG00000121753.13. [O60241-4]
DR   GeneID; 576; -.
DR   KEGG; hsa:576; -.
DR   MANE-Select; ENST00000373658.8; ENSP00000362762.3; NM_001364857.2; NP_001351786.1.
DR   UCSC; uc001btn.4; human. [O60241-1]
DR   AGR; HGNC:944; -.
DR   CTD; 576; -.
DR   DisGeNET; 576; -.
DR   GeneCards; ADGRB2; -.
DR   HGNC; HGNC:944; ADGRB2.
DR   HPA; ENSG00000121753; Tissue enriched (brain).
DR   MIM; 602683; gene.
DR   neXtProt; NX_O60241; -.
DR   OpenTargets; ENSG00000121753; -.
DR   PharmGKB; PA25248; -.
DR   VEuPathDB; HostDB:ENSG00000121753; -.
DR   eggNOG; ENOG502QRKJ; Eukaryota.
DR   GeneTree; ENSGT00940000160103; -.
DR   InParanoid; O60241; -.
DR   OMA; NILMPMA; -.
DR   OrthoDB; 4181250at2759; -.
DR   PhylomeDB; O60241; -.
DR   TreeFam; TF331634; -.
DR   PathwayCommons; O60241; -.
DR   SignaLink; O60241; -.
DR   BioGRID-ORCS; 576; 24 hits in 772 CRISPR screens.
DR   ChiTaRS; ADGRB2; human.
DR   GeneWiki; Brain-specific_angiogenesis_inhibitor_2; -.
DR   GenomeRNAi; 576; -.
DR   Pharos; O60241; Tbio.
DR   PRO; PR:O60241; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; O60241; protein.
DR   Bgee; ENSG00000121753; Expressed in right frontal lobe and 130 other tissues.
DR   ExpressionAtlas; O60241; baseline and differential.
DR   Genevisible; O60241; HS.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; TAS:GDB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IMP:UniProtKB.
DR   GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0033173; P:calcineurin-NFAT signaling cascade; IMP:UniProtKB.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IEA:InterPro.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; IEA:InterPro.
DR   GO; GO:0007422; P:peripheral nervous system development; IBA:GO_Central.
DR   CDD; cd15988; 7tmB2_BAI2; 1.
DR   Gene3D; 1.25.40.610; -; 1.
DR   Gene3D; 2.60.220.50; -; 1.
DR   Gene3D; 4.10.1240.10; GPCR, family 2, extracellular hormone receptor domain; 1.
DR   Gene3D; 1.20.1070.10; Rhodopsin 7-helix transmembrane proteins; 1.
DR   Gene3D; 2.20.100.10; Thrombospondin type-1 (TSP1) repeat; 4.
DR   InterPro; IPR043838; AGRB_N.
DR   InterPro; IPR032471; GAIN_dom_N.
DR   InterPro; IPR046338; GAIN_dom_sf.
DR   InterPro; IPR017981; GPCR_2-like_TM.
DR   InterPro; IPR008077; GPCR_2_brain_angio_inhib.
DR   InterPro; IPR036445; GPCR_2_extracell_dom_sf.
DR   InterPro; IPR001879; GPCR_2_extracellular_dom.
DR   InterPro; IPR000832; GPCR_2_secretin-like.
DR   InterPro; IPR000203; GPS.
DR   InterPro; IPR000884; TSP1_rpt.
DR   InterPro; IPR036383; TSP1_rpt_sf.
DR   PANTHER; PTHR10239:SF22; ADHESION G PROTEIN-COUPLED RECEPTOR B2; 1.
DR   PANTHER; PTHR10239; ISTHMIN-2; 1.
DR   Pfam; PF00002; 7tm_2; 1.
DR   Pfam; PF19188; AGRB_N; 1.
DR   Pfam; PF16489; GAIN; 1.
DR   Pfam; PF01825; GPS; 1.
DR   Pfam; PF00090; TSP_1; 4.
DR   PRINTS; PR01694; BAIPRECURSOR.
DR   PRINTS; PR00249; GPCRSECRETIN.
DR   SMART; SM00303; GPS; 1.
DR   SMART; SM00008; HormR; 1.
DR   SMART; SM00209; TSP1; 4.
DR   SUPFAM; SSF81321; Family A G protein-coupled receptor-like; 1.
DR   SUPFAM; SSF82895; TSP-1 type 1 repeat; 4.
DR   PROSITE; PS50227; G_PROTEIN_RECEP_F2_3; 1.
DR   PROSITE; PS50261; G_PROTEIN_RECEP_F2_4; 1.
DR   PROSITE; PS50221; GPS; 1.
DR   PROSITE; PS50092; TSP1; 4.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; Direct protein sequencing;
KW   Disease variant; Disulfide bond; G-protein coupled receptor; Glycoprotein;
KW   Membrane; Phosphoprotein; Proteoglycan; Receptor; Reference proteome;
KW   Repeat; Secreted; Signal; Transducer; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..32
FT                   /evidence="ECO:0000255"
FT   CHAIN           33..1585
FT                   /note="Adhesion G protein-coupled receptor B2"
FT                   /id="PRO_0000012864"
FT   TOPO_DOM        33..936
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        937..957
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        958..965
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        966..986
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        987..994
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        995..1015
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        1016..1036
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1037..1057
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        1058..1078
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1079..1099
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        1100..1121
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1122..1142
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        1143..1153
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1154..1174
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        1175..1585
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   DOMAIN          309..362
FT                   /note="TSP type-1 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DOMAIN          364..417
FT                   /note="TSP type-1 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DOMAIN          419..472
FT                   /note="TSP type-1 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DOMAIN          475..528
FT                   /note="TSP type-1 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DOMAIN          871..923
FT                   /note="GPS"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00098"
FT   REGION          229..271
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          767..806
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1359..1385
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1423..1454
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1498..1585
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        229..244
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            296..297
FT                   /note="Cleavage; by furin"
FT                   /evidence="ECO:0000269|PubMed:20367554"
FT   MOD_RES         1351
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8CGM1"
FT   CARBOHYD        106
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        191
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        192
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        266
FT                   /note="O-linked (Xyl...) (chondroitin sulfate) serine"
FT                   /evidence="ECO:0000269|PubMed:25326458"
FT   CARBOHYD        356
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        437
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        560
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        645
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        867
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        321..355
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DISULFID        325..361
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DISULFID        336..345
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DISULFID        376..411
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DISULFID        380..416
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DISULFID        391..401
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DISULFID        431..466
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DISULFID        435..471
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DISULFID        446..456
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DISULFID        487..522
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DISULFID        491..527
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DISULFID        502..512
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DISULFID        534..569
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DISULFID        557..587
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DISULFID        874..906
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DISULFID        894..908
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   VAR_SEQ         1..12
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_037045"
FT   VAR_SEQ         1119..1151
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_037046"
FT   VAR_SEQ         1473
FT                   /note="Missing (in isoform 2 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:9533023"
FT                   /id="VSP_037047"
FT   VARIANT         1465
FT                   /note="R -> W (probable disease-associated variant found in
FT                   a patient with progressive spastic paraparesis and other
FT                   neurological symptoms; enhances receptor surface
FT                   expression; increases the constitutive signaling activity;
FT                   does not affect interaction with GNAZ; promotes enhanced
FT                   interaction with GNAI1; decreases interaction with SH3GL2;
FT                   dbSNP:rs778361520)"
FT                   /evidence="ECO:0000269|PubMed:28891236"
FT                   /id="VAR_079840"
FT   MUTAGEN         889
FT                   /note="W->S: Inhibits autoproteolytic cleavage."
FT                   /evidence="ECO:0000269|PubMed:20367554"
FT   MUTAGEN         908
FT                   /note="C->W: Inhibits autoproteolytic cleavage."
FT                   /evidence="ECO:0000269|PubMed:20367554"
FT   MUTAGEN         912
FT                   /note="S->P: Inhibits autoproteolytic cleavage."
FT                   /evidence="ECO:0000269|PubMed:20367554"
FT   CONFLICT        325
FT                   /note="C -> R (in Ref. 4; AAI36534)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1585 AA;  172656 MW;  56D253AE0AB1552D CRC64;
     MENTGWMGKG HRMTPACPLL LSVILSLRLA TAFDPAPSAC SALASGVLYG AFSLQDLFPT
     IASGCSWTLE NPDPTKYSLY LRFNRQEQVC AHFAPRLLPL DHYLVNFTCL RPSPEEAVAQ
     AESEVGRPEE EEAEAAAGLE LCSGSGPFTF LHFDKNFVQL CLSAEPSEAP RLLAPAALAF
     RFVEVLLINN NNSSQFTCGV LCRWSEECGR AAGRACGFAQ PGCSCPGEAG AGSTTTTSPG
     PPAAHTLSNA LVPGGPAPPA EADLHSGSSN DLFTTEMRYG EEPEEEPKVK TQWPRSADEP
     GLYMAQTGDP AAEEWSPWSV CSLTCGQGLQ VRTRSCVSSP YGTLCSGPLR ETRPCNNSAT
     CPVHGVWEEW GSWSLCSRSC GRGSRSRMRT CVPPQHGGKA CEGPELQTKL CSMAACPVEG
     QWLEWGPWGP CSTSCANGTQ QRSRKCSVAG PAWATCTGAL TDTRECSNLE CPATDSKWGP
     WNAWSLCSKT CDTGWQRRFR MCQATGTQGY PCEGTGEEVK PCSEKRCPAF HEMCRDEYVM
     LMTWKKAAAG EIIYNKCPPN ASGSASRRCL LSAQGVAYWG LPSFARCISH EYRYLYLSLR
     EHLAKGQRML AGEGMSQVVR SLQELLARRT YYSGDLLFSV DILRNVTDTF KRATYVPSAD
     DVQRFFQVVS FMVDAENKEK WDDAQQVSPG SVHLLRVVED FIHLVGDALK AFQSSLIVTD
     NLVISIQREP VSAVSSDITF PMRGRRGMKD WVRHSEDRLF LPKEVLSLSS PGKPATSGAA
     GSPGRGRGPG TVPPGPGHSH QRLLPADPDE SSYFVIGAVL YRTLGLILPP PRPPLAVTSR
     VMTVTVRPPT QPPAEPLITV ELSYIINGTT DPHCASWDYS RADASSGDWD TENCQTLETQ
     AAHTRCQCQH LSTFAVLAQP PKDLTLELAG SPSVPLVIGC AVSCMALLTL LAIYAAFWRF
     IKSERSIILL NFCLSILASN ILILVGQSRV LSKGVCTMTA AFLHFFFLSS FCWVLTEAWQ
     SYLAVIGRMR TRLVRKRFLC LGWGLPALVV AVSVGFTRTK GYGTSSYCWL SLEGGLLYAF
     VGPAAVIVLV NMLIGIIVFN KLMARDGISD KSKKQRAGSE RCPWASLLLP CSACGAVPSP
     LLSSASARNA MASLWSSCVV LPLLALTWMS AVLAMTDRRS VLFQALFAVF NSAQGFVITA
     VHCFLRREVQ DVVKCQMGVC RADESEDSPD SCKNGQLQIL SDFEKDVDLA CQTVLFKEVN
     TCNPSTITGT LSRLSLDEDE EPKSCLVGPE GSLSFSPLPG NILVPMAASP GLGEPPPPQE
     ANPVYMCGEG GLRQLDLTWL RPTEPGSEGD YMVLPRRTLS LQPGGGGGGG EDAPRARPEG
     TPRRAAKTVA HTEGYPSFLS VDHSGLGLGP AYGSLQNPYG MTFQPPPPTP SARQVPEPGE
     RSRTMPRTVP GSTMKMGSLE RKKLRYSDLD FEKVMHTRKR HSELYHELNQ KFHTFDRYRS
     QSTAKREKRW SVSSGGAAER SVCTDKPSPG ERPSLSQHRR HQSWSTFKSM TLGSLPPKPR
     ERLTLHRAAA WEPTEPPDGD FQTEV
//
